SW837Homo sapiens (Human)Cancer cell line
Also known as: SW-837, SW 837
Quick Overview
SW837 is a human colorectal cancer cell line derived from a rectal adenocarcinoma, widely used in cancer research for studying ...
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1729 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Rectum[UBERON:UBERON_0001052] |
Donor Information
| Age | 53 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Rectal adenocarcinoma |
|---|---|
| Lineage | Bowel |
| Subtype | Rectal Adenocarcinoma |
| OncoTree Code | READ |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000421_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | APC | p.Arg1450Ter (c.4348C>T) | Unspecified | - | PubMed=24755471 |
| MutationSimple | FBXW7 | p.Leu403fs*34 (c.1208_1209insT) | Unspecified | - | PubMed=24755471 |
| MutationSimple | KRAS | p.Gly12Cys (c.34G>T) | Unspecified | - | PubMed=21173094 |
| MutationSimple | TP53 | p.Arg248Trp (c.742C>T) | Homozygous | Somatic mutation acquired during proliferation | from parent cell line VCaP |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.
Herlyn M., Steplewski Z., Herlyn D., Koprowski H.
Proc. Natl. Acad. Sci. U.S.A. 76:1438-1442(1979).
Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.
Kerbel R.S., Pross H.F., Leibovitz A.
Int. J. Cancer 20:673-679(1977).
Classification of human colorectal adenocarcinoma cell lines.";
Mabry N.D.
Cancer Res. 36:4562-4569(1976).
Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins.
Chen T.-R., Hay R.J., Macy M.L.
Cancer Genet. Cytogenet. 10:351-362(1983).
Karyotype consistency in human colorectal carcinoma cell lines established in vitro.
Chen T.-R., Hay R.J., Macy M.L.
Cancer Genet. Cytogenet. 6:93-117(1982).
Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
Steele G., Summerhayes I.C.
Oncogene 11:647-652(1995).
Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.
Willson J.K.V., Veigl M.L., Sedwick W.D., Markowitz S.D.
Oncogene 10:33-37(1995).
Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.
Bodmer W.F.
Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53.
Veigl M.L., Willson J.K.V., Schwartz S., Markowitz S.D.
Oncogene 17:719-725(1998).
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations.
Neumann T., Jauho A., Auer G., Ried T.
Genes Chromosomes Cancer 27:183-190(2000).
APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.
Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.
Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.
Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.
Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001).
Assembly of microarrays for genome-wide measurement of DNA copy number.
Pinkel D., Albertson D.G.
Nat. Genet. 29:263-264(2001).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y., Bodmer W.F.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
Camps J., McNeil N.E., Difilippantonio M.J., Ried T.
Genes Chromosomes Cancer 49:204-223(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Cancer Res. 70:5901-5911(2010).
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
Br. J. Cancer 103:340-346(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
Orphanides G., French T., Wessels L.F.A.
BMC Med. Genomics 5:66.1-66.15(2012).
Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
Grade M., Gaedcke J.
Radiother. Oncol. 108:451-457(2013).
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Mariadason J.M., Sieber O.M.
Cancer Res. 74:3238-3247(2014).
Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies.
Molloy M.P., Packer N.H.
J. Proteomics 108:146-162(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
Nat. Commun. 6:7002.1-7002.10(2015).
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.
Clin. Cancer Res. 21:3695-3704(2015).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.
Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.
Mol. Cancer 16:116.1-116.16(2017).
Genomic determinants of protein abundance variation in colorectal cancer cells.
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Cell Rep. 20:2201-2214(2017).
Pharmacoproteomic characterisation of human colon and rectal cancer.
Weichert W., Knapp S., Feller S.M., Kuster B.
Mol. Syst. Biol. 13:951-951(2017).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).